Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround.
He says investors are still underestimating the promise of the company’s drugs.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.nytimes.com — the content belongs to The New York Times.
